Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Oxford Nanopore Technologies Collaborates with Twist Bioscience to Launch Pharmacogenomics Beta Program

NextEdge Admin

22 May 2024

2 min 17 sec

Oxford Nanopore Technologies announced a collaboration with Twist Bioscience to introduce a beta program focused on pharmacogenomics for personalized medicine. Financial specifics of the partnership were not disclosed. This initiative merges Twist’s next-gen sequencing library prep reagents and target enrichment panels with Oxford Nanopore’s MinIon and PromethIon sequencing platforms to devise long-read pharmacogenomics workflows.

Presently tailored for research applications, these workflows aim to furnish unequivocal genetic outcomes in one seamless process from sample to pharmacogenomics star allele identification, potentially obviating the need for subsequent testing. Oxford Nanopore reports successful resolution of the CYP2D6 gene in a single assay within the beta program. Moreover, the companies intend to render Twist’s hybrid capture panels, such as the Twist Alliance Dark Genes Panel and the Twist Exome 2.0, compatible with Oxford Nanopore’s platforms.

Emily Leproust, Twist’s Co-founder and CEO, expressed enthusiasm about broadening the scope of their NGS products and empowering researchers to advance personalized therapies through this collaboration. She highlighted anticipation for progress within the beta program and potential expansions in their partnership.

Gordon Sanghera, CEO of Oxford Nanopore, underscored the value proposition of their collaboration with Twist in the pharmacogenomics realm. Sanghera emphasized Oxford Nanopore’s capability to furnish comprehensive and efficient genetic analysis in clinical settings, leveraging the advantages of long reads, rapid sequencing, compact form factors, and adaptable throughput. He affirmed their commitment to enhancing genetic analysis through this collaboration.